aTyr Pharma reports Q1 2023 cash of $117.6M; Phase 3 sarcoidosis trial enrolling

aTYR PHARMA INC

2023-Q1 EPS reported -$0.29

Cash, equivalents and investments of $117.6M as of March 31, 2023; $48.1M net from February stock offering.
Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling in U.S., Europe and Japan; up to 264 subjects.
Phase 2 proof-of-concept study in SSc-ILD expected to initiate Q3 2023; 25 patients, multiple U.S. centers.
R&D expenses $9.4M and G&A expenses $3.4M for Q1 2023; cash runway projected into 2026.
Multiple efzofitimod presentations planned at ATS 2023 International Conference May 19-24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

aTYR PHARMA INC updated its three months ended March 31, 2023 guidance (reaffirmed).

Period: three months ended March 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2023.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-23-019633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.